M
Moximed
Minimizing joint pain, restoring normal activity levels, and slowing disease progression
About Moximed
Moximed is a medical technology startup that specializes in the development and distribution of the MISHA Knee System, an implantable shock absorber (ISA) for the knee. This innovative product is designed to alleviate pain and improve function for patients suffering from medial knee osteoarthritis (OA), a condition that causes pain and inflammation in the knee joint.
The company's primary clients are healthcare providers who treat patients with knee OA, particularly those who have not found relief from non-surgical or surgical treatments, continue to experience pain that interferes with daily activities, or are ineligible for or unwilling to undergo arthroplasty (joint replacement surgery) due to age or absence of advanced arthritis.
Moximed operates in the medical device market, a sector that is expected to grow as the global population ages and the prevalence of conditions like OA increases. The company's business model revolves around the sale of the MISHA Knee System to healthcare providers.
The MISHA Knee System is marketed as a quick and efficient solution for knee OA, offering patients a swift recovery time and the ability to return to normal activities within days. This positions Moximed as a provider of innovative, patient-centric solutions that not only improve the quality of life for patients but also enhance the practice of healthcare providers who incorporate the MISHA Knee System into their treatment offerings.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2006
- Headquarters
- Fremont, United States
- Employees
- 78
- Open positions
- 18
- Dealroom signal
- 87.2/100
- Industry
- Health
- Sub-industry
- BioTechnology, Medical Devices
- Sector
- Biotech & Life Sciences, Biotechnology, Polymers, Biotech and Pharma, Hard Tech, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2c
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES DOther financing | Aug 2024 | $61M | $244M | Gilde Healthcare · Advent Life Sciences · Cormorant Asset Management · GBS Venture Partners | ↗ |
| LATE VCOther financing | Feb 2024 | $0 | — | Warren Point Capital | ↗ |
Growth signals
Latest recorded traffic for Moximed is 4K monthly website visits, up 21.2% over the last three months. Moximed's team grew 2.6% over the past year.
Open positions
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed1 investor entered at this stage
ExploraMed
Series A8 investors entered at this stage
NEA- MVMorgenthaler Ventures
Gilde Healthcare
Frazier Healthcare Partners
Vertex Holdings
Glide Health
GBS Venture Partners- VCVertex Venture Capital
Series B and later7 investors entered at this stage
Advent Life Sciences
Future Fund
Runway Growth Capital
Vertex Ventures HC
Warren Point Capital
Elevage Medical Technologies
Cormorant Asset Management
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Moximed on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Moximed’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.